Teneligliptin Hydrobromide is a significant DPP-4 inhibitor with potent glucose-lowering effects and favorable pharmacokinetic properties, offering valuable clinical applications in the management of type 2 diabetes.
Basic Information
English Name: Teneligliptin Hydrobromide
CAS Registry Number: 906093-29-6
Chemical Formula: C44H65Br5N12O2S2
Molecular Weight: 1257.72
Pharmacological Action
Teneligliptin Hydrobromide is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the treatment of type 2 diabetes mellitus. By inhibiting DPP-4 activity, it enhances the levels of active glucagon-like peptide-1 (GLP-1) in the bloodstream, thereby reducing blood glucose levels. Additionally, Teneligliptin exhibits antioxidant properties, ameliorating high glucose-induced endoplasmic reticulum stress and promoting antioxidant responses in human umbilical vein endothelial cells, reducing ROS levels, and inducing Nrf2 target gene mRNA expression.
Pharmacokinetics
Bioavailability: High bioavailability upon oral administration.
Metabolism: Metabolism of Teneligliptin primarily involves CYP3A4 and flavin-containing monooxygenases (FMO1 and FMO3).
Excretion: A significant portion of the administered dose is excreted unchanged in urine, with some excretion occurring via feces.
